Nitric oxide suppresses the secretion of vascular endothelial growth factor and hepatocyte growth factor from human mesenchymal stem cells

Yue Wang, Paul R. Crisostomo, Meijing Wang, Brent Weil, Aaron Abarbanell, Jeffrey Poynter, Mariuxi C. Manukyan, Daniel R. Meldrum

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The production of growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) by human bone marrow mesenchymal stem cells (MSCs) may play an important role in their paracrine effects on proliferation, differentiation, and protection. NO is produced during ischemia and may affect MSC function. However, it is unknown whether NO alters the production of VEGF and HGF from MSCs. To study this, human MSCs were stimulated to produce growth factors with TNF or LPS with and without various doses of NO donors or NOS inhibitors. We found that FK409, an NO donor, significantly suppressed the production of VEGF and HGF from human MSCs. Vascular endothelial growth factor in the supernatants of cells treated by 20 nM FK409 (497 ± 19 pg/mL) was significantly lower compared with controls (625 ± 34 pg/mL). Similarly, NO donor significantly suppressed the amount of HGF from controls (118 ± 3 to 40 ± 2 pg/mL) after treatment with 20 nM FK409. NO donor also abolished the augmentation of VEGF production induced by LPS. The amount of VEGF in the supernatant was 571 ± 11 pg/mL when cells were treated with 20 nM FK409 and LPS (200 ng/mL), which was significantly lower than groups treated with LPS alone (941 ± 30 pg/mL). This study constitutes an initial report regarding the effect of NO on human MSC growth factor production.

Original languageEnglish
Pages (from-to)527-531
Number of pages5
JournalShock
Volume30
Issue number5
DOIs
StatePublished - Nov 2008

Fingerprint

Mesenchymal Stromal Cells
Vascular Endothelial Growth Factor A
Nitric Oxide
Intercellular Signaling Peptides and Proteins
Hepatocyte Growth Factor
Stem Cell Factor
human HGF protein
Ischemia
Bone Marrow

Keywords

  • HGF
  • Ischemia
  • LPS
  • NOS
  • Reperfusion
  • TNF
  • VEGF

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Cite this

Nitric oxide suppresses the secretion of vascular endothelial growth factor and hepatocyte growth factor from human mesenchymal stem cells. / Wang, Yue; Crisostomo, Paul R.; Wang, Meijing; Weil, Brent; Abarbanell, Aaron; Poynter, Jeffrey; Manukyan, Mariuxi C.; Meldrum, Daniel R.

In: Shock, Vol. 30, No. 5, 11.2008, p. 527-531.

Research output: Contribution to journalArticle

Wang, Yue ; Crisostomo, Paul R. ; Wang, Meijing ; Weil, Brent ; Abarbanell, Aaron ; Poynter, Jeffrey ; Manukyan, Mariuxi C. ; Meldrum, Daniel R. / Nitric oxide suppresses the secretion of vascular endothelial growth factor and hepatocyte growth factor from human mesenchymal stem cells. In: Shock. 2008 ; Vol. 30, No. 5. pp. 527-531.
@article{39269f20148b430f9ab6973d53ae206f,
title = "Nitric oxide suppresses the secretion of vascular endothelial growth factor and hepatocyte growth factor from human mesenchymal stem cells",
abstract = "The production of growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) by human bone marrow mesenchymal stem cells (MSCs) may play an important role in their paracrine effects on proliferation, differentiation, and protection. NO is produced during ischemia and may affect MSC function. However, it is unknown whether NO alters the production of VEGF and HGF from MSCs. To study this, human MSCs were stimulated to produce growth factors with TNF or LPS with and without various doses of NO donors or NOS inhibitors. We found that FK409, an NO donor, significantly suppressed the production of VEGF and HGF from human MSCs. Vascular endothelial growth factor in the supernatants of cells treated by 20 nM FK409 (497 ± 19 pg/mL) was significantly lower compared with controls (625 ± 34 pg/mL). Similarly, NO donor significantly suppressed the amount of HGF from controls (118 ± 3 to 40 ± 2 pg/mL) after treatment with 20 nM FK409. NO donor also abolished the augmentation of VEGF production induced by LPS. The amount of VEGF in the supernatant was 571 ± 11 pg/mL when cells were treated with 20 nM FK409 and LPS (200 ng/mL), which was significantly lower than groups treated with LPS alone (941 ± 30 pg/mL). This study constitutes an initial report regarding the effect of NO on human MSC growth factor production.",
keywords = "HGF, Ischemia, LPS, NOS, Reperfusion, TNF, VEGF",
author = "Yue Wang and Crisostomo, {Paul R.} and Meijing Wang and Brent Weil and Aaron Abarbanell and Jeffrey Poynter and Manukyan, {Mariuxi C.} and Meldrum, {Daniel R.}",
year = "2008",
month = "11",
doi = "10.1097/SHK.0b013e31816f1ec9",
language = "English",
volume = "30",
pages = "527--531",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Nitric oxide suppresses the secretion of vascular endothelial growth factor and hepatocyte growth factor from human mesenchymal stem cells

AU - Wang, Yue

AU - Crisostomo, Paul R.

AU - Wang, Meijing

AU - Weil, Brent

AU - Abarbanell, Aaron

AU - Poynter, Jeffrey

AU - Manukyan, Mariuxi C.

AU - Meldrum, Daniel R.

PY - 2008/11

Y1 - 2008/11

N2 - The production of growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) by human bone marrow mesenchymal stem cells (MSCs) may play an important role in their paracrine effects on proliferation, differentiation, and protection. NO is produced during ischemia and may affect MSC function. However, it is unknown whether NO alters the production of VEGF and HGF from MSCs. To study this, human MSCs were stimulated to produce growth factors with TNF or LPS with and without various doses of NO donors or NOS inhibitors. We found that FK409, an NO donor, significantly suppressed the production of VEGF and HGF from human MSCs. Vascular endothelial growth factor in the supernatants of cells treated by 20 nM FK409 (497 ± 19 pg/mL) was significantly lower compared with controls (625 ± 34 pg/mL). Similarly, NO donor significantly suppressed the amount of HGF from controls (118 ± 3 to 40 ± 2 pg/mL) after treatment with 20 nM FK409. NO donor also abolished the augmentation of VEGF production induced by LPS. The amount of VEGF in the supernatant was 571 ± 11 pg/mL when cells were treated with 20 nM FK409 and LPS (200 ng/mL), which was significantly lower than groups treated with LPS alone (941 ± 30 pg/mL). This study constitutes an initial report regarding the effect of NO on human MSC growth factor production.

AB - The production of growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) by human bone marrow mesenchymal stem cells (MSCs) may play an important role in their paracrine effects on proliferation, differentiation, and protection. NO is produced during ischemia and may affect MSC function. However, it is unknown whether NO alters the production of VEGF and HGF from MSCs. To study this, human MSCs were stimulated to produce growth factors with TNF or LPS with and without various doses of NO donors or NOS inhibitors. We found that FK409, an NO donor, significantly suppressed the production of VEGF and HGF from human MSCs. Vascular endothelial growth factor in the supernatants of cells treated by 20 nM FK409 (497 ± 19 pg/mL) was significantly lower compared with controls (625 ± 34 pg/mL). Similarly, NO donor significantly suppressed the amount of HGF from controls (118 ± 3 to 40 ± 2 pg/mL) after treatment with 20 nM FK409. NO donor also abolished the augmentation of VEGF production induced by LPS. The amount of VEGF in the supernatant was 571 ± 11 pg/mL when cells were treated with 20 nM FK409 and LPS (200 ng/mL), which was significantly lower than groups treated with LPS alone (941 ± 30 pg/mL). This study constitutes an initial report regarding the effect of NO on human MSC growth factor production.

KW - HGF

KW - Ischemia

KW - LPS

KW - NOS

KW - Reperfusion

KW - TNF

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=55649118693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649118693&partnerID=8YFLogxK

U2 - 10.1097/SHK.0b013e31816f1ec9

DO - 10.1097/SHK.0b013e31816f1ec9

M3 - Article

C2 - 18391852

AN - SCOPUS:55649118693

VL - 30

SP - 527

EP - 531

JO - Shock

JF - Shock

SN - 1073-2322

IS - 5

ER -